News | Radiology Business | October 06, 2023

Bawendi’s expertise in optics, fluorescent molecules and tissue imaging were instrumental in development of Lumicell Direct Visualization System, which is currently under FDA review

Bawendi’s expertise in optics, fluorescent molecules and tissue imaging were instrumental in development of Lumicell Direct Visualization System, which is currently under FDA review

Moungi G. Bawendi, PhD


October 6, 2023 — Lumicell, Inc., a privately held company focused on innovative fluorescence-guided imaging technologies for cancer surgery, today announced company co-founder Moungi G. Bawendi, PhD, is one of three recipients of the Nobel Prize in Chemistry 2023 for the discovery and synthesis of quantum dots.

The investigational Lumicell Direct Visualization System (DVS), which is designed to assist in the detection of residual cancerous tissue during lumpectomy using fluorescence imaging, was developed in Bawendi’s lab at the Massachusetts Institute of Technology (MIT). His expertise in optics and tissue imaging guided the design and invention of the imaging device, and his expertise in the physio-chemical properties of fluorescent molecules led to the design of the company’s imaging agent LUMISIGHT.

“It’s exciting to see Professor Bawendi’s research into quantum dots, which has enabled breakthroughs in medical imaging, display technology and electronic materials, recognized with the top scientific prize in the world,” said Jorge Ferrer, PhD, senior vice president, clinical research and strategy at Lumicell, and co-inventor of Lumicell’s technology developed at Bawendi’s MIT lab. “His expertise has been instrumental in the development of our investigational Lumicell Direct Visualization System, and he continues to be an important scientific advisor as we work toward FDA approval of the Lumicell DVS for breast cancer and embark on the development of new imaging technologies to expand into other cancers.”

The Lumicell DVS has been evaluated in more than 700 breast cancer patients across five clinical studies at top academic and regional community cancer centers. The New Drug Application (NDA) for the LUMISIGHT Optical Imaging Agent and Premarket Approval (PMA) application for the Lumicell Direct Visualization System (DVS) are currently under review by the U.S. Food & Drug Administration. 

About the Lumicell Direct Visualization System and LUMISIGHT Optical Imaging Agent

The Lumicell DVS is an investigational system designed for use in patients with breast cancer to assist in the detection of residual malignant tissue within the lumpectomy cavity following removal of the primary specimen during breast conserving surgery. The investigational Lumicell Direct Visualization System (DVS) is intended for use with the investigational LUMISIGHT Optical Imaging Agent and features a hand-held imaging probe that is designed to go inside the breast cavity and a patient-calibrated cancer detection software to assist in the detection of residual cancer, thereby enabling a more complete cancer resection. Lumicell’s proprietary, pan-oncologic optical imaging agent LUMISIGHT is also being explored across a wide variety of solid tumor indications.

The Lumicell DVS and LUMISIGHT are limited by Federal (or United States) law to investigational use only. The Lumicell DVS and LUMISIGHT are not commercially available.

For more information: www.lumicell.com

Related content:

Lumicell Submits New Drug Application for Lumisight Optical Imaging Agent to U.S. FDA for Intraoperative Breast Cancer Detection and Removal


Related Content

Feature | RSNA | Christine Book

November 29, 2023 — Following the theme of the Radiological Society of North America Scientific Assembly and Annual ...

Time November 29, 2023
arrow
News | Artificial Intelligence

November 28, 2023 — iCAD, Inc., a global medical technology leader in innovative cancer-detection solutions, and ...

Time November 28, 2023
arrow
News | RSNA

November 28, 2023 — iCAD, Inc., a global medical technology company developing cancer-detection solutions, will present ...

Time November 28, 2023
arrow
Feature | RSNA | Christine Book

November 28, 2023 — By early Monday morning, on the second day of RSNA 2023, there were significant news announcements ...

Time November 28, 2023
arrow
News | Artificial Intelligence

November 27, 2023 — Mass General Brigham and Annalise.ai today announced a collaboration to bring together their ...

Time November 27, 2023
arrow
News | RSNA

November 27, 2023 — The executive leadership teams from Canon Inc. and Cleveland Clinic gathered early on day two of the ...

Time November 27, 2023
arrow
News | Breast Imaging

November 27, 2023 — Barco announces introduction of the DL Precise AI software in addition to the current Intuitive ...

Time November 27, 2023
arrow
News | Digital Pathology

November 27, 2023 — At the Radiological Society of North America's (RSNA) 109th Scientific Assembly and Annual Meeting ...

Time November 27, 2023
arrow
Feature | RSNA | Christine Book

November 27, 2023 — The President’s Address during the RSNA 2023 Opening Session at Sunday's first Plenary program ...

Time November 27, 2023
arrow
Feature | RSNA

November 27, 2023 — The collective anticipation of the radiology community was palpable from early morning through ...

Time November 27, 2023
arrow
Subscribe Now